COVID-19: Alarm over clamour for hydroxychloroquine
There's rising interest in the drug to fight coronavirus, but this could threaten supply for current indications, warn rheumatologists
The TGA has restricted initiation of hydroxychloroquine to specialists in the wake of concern about a run on the drug for off-label use as prophylaxis against COVID-19.
The Australian Rheumatology Association (ARA) and Pharmaceutical Society of Australia have each raised concerns about the potential for supply shortages of the drug, which is in several trials worldwide as a potential therapy or preventive for coronavirus.
